SCHEMBL980945

SCHEMBL980945

CS(=O)(=O)c1ccc(CC(=O)N2CCC(c3ccc(Cl)cc3)=N2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 1/20 0.46
PGR P06401 2/20 0.44
GAA P10253 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
S1PR2 O95136 1/20 0.43
S1PR4 O95977 1/20 0.43
GLA P06280 1/20 0.43
S1PR1 P21453 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ERAP1 Q9NZ08 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CCR2 P41597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982309 0.88 ALDH1A1 (0.43) PTGS2ALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL982007 0.84 ME2 (0.51) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL981953 0.83 MEN1 (0.52) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL979242 0.83 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL981878 0.81 ALDH1A1 (0.44) PTGS2ALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL980870 0.76 MAOB (0.53) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL981498 0.76 ALDH1A1 (0.48) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL980150 0.76 ALDH1A1 (0.76) ALDH1A1HPGDSMN1; SMN2RAB9AGAA
SCHEMBL980254 0.76 PGR (0.46) ALDH1A1HPGDSMN1; SMN2RAB9APGR
SCHEMBL981926 0.75 ALDH1A1 (0.57) ALDH1A1HPGDSMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 PTGS2 2918/4885ALDH1A1 399/4885HPGD 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.